Cystatin C

摘要： Objective: To establish the diagnostic concentration range of urine cystatin C and the control level of urine cystatin C for patients with renal injury, and to help promote the establishment of standardization of urine cystatin C detection. Methods: 150 urine specimens and blood specimens from kidney injury patients and healthy people were collected, and stored in the refrigerator at -80°C for later use. After the specimens were collected, they were uniformly tested. Comparing the difference of blood and urine cystatin C between the kidney injury group and the healthy control group, the application value of urine cystatin C in the diagnosis and treatment of kidney injury was put forward. Results: The concentrations of cystatin C in urine and blood of renal injury group were 1.04 ± 2.14 mg/L and 1.94 ± 2.36 mg/L respectively;the concentrations of cystatin C in urine and blood of healthy control group were 0.11 ± 0.05 mg/L and 0.83 ± 0.20 mg/L respectively. The urine and blood cystatin C of the kidney injury group were significantly higher than those of the healthy control group. Compared the results of the two groups, the t values were 5.3210 and 5.7399, respectively. The P value is 0.0000;the difference is statistically significant;in comparison of urine and blood cystatin C in the kidney injury group, the value is that t = 3.4600, P = 0.0003;in comparison of urine and blood cystatin C in the healthy control group, the value is that t = 42.7744, P = 0.0000. By investigating the urine cystatin C concentration of patients with kidney injury, whether it is kidney injury or healthy controls, urine cystatin C is significantly lower than blood cystatin C. Conclusion: According to the results of this study, the concentration of urinary cystatin C in the healthy control group is 0.11 ± 0.05 mg/L. The reference interval of urinary cystatin C proposed in this study is 0.06 - 0.16 mg/L, which can be established by comprehensive multi center research. Through a multi-center study of the baseline level of urinary cystatin C in patients with renal injury, the diagnostic concentration interval of urinary cystatin C and the control level of urine cystatin C for renal injury patients were established.

摘要： BACKGROUND The outbreak of coronavirus disease 2019(COVID-19)has rapidly evolved into a global pandemic.COVID-19 is clinically categorized into mild,moderate,severe,and critical illness.Acute kidney injury is an independent risk factor for poor prognosis in patients with.Serum cystatin C(s Cys C)is considered a more sensitive biomarker for early renal insufficiency than conventional indicators of renal function.Early detection of risk factors that affect the prognosis of severe and critically ill patients while using active and effective treatment measures is very important and can effectively reduce the potential mortality rate.AIM To determine the predictive value of s Cys C for the prognosis of patients with COVID-19.METHODS The clinical data of 101 severe and critically ill patients with COVID-19 at a designated hospital in Wuhan,Hubei Province,China were analyzed retrospectively.According to the clinical outcome,the patients were divided into a discharge group(64 cases)and a death group(37 cases).The general information,underlying diseases,and laboratory examination indexes of the two groups were compared.Multivariate Cox regression was used to explore the relationship between s Cys C and prognosis.The receiver operating characteristic(ROC)curve was used to demonstrate the sensitivity and specificity of s Cys C and its optimal cut-off value for predicting death.RESULTS There were significant differences in age,s Cys C,creatinine,C-reactive protein,serum albumin,creatine kinase-MB,alkaline phosphatase,lactate dehydrogenase,neutrophil count,and lymphocyte count between the two groups(P<0.001).Multivariate logistic regression analysis showed that s Cys C was an independent risk factor for death in patients with COVID-19(Odds ratio=1.812,95%confidence interval[CI]:1.300-2.527,P<0.001).The area under the ROC curve was 0.755(95%CI:1.300-2.527),the cut-off value was 0.80,the specificity was 0.562,and the sensitivity was 0.865.CONCLUSION s Cys C is an independent risk factor for death in patients with COVID-19.Patients with a s Cys C level of 0.80 mg/L or greater are at a high risk of death.

摘要： 目的 探讨NGAL(中性粒细胞明胶酶相关脂质运载蛋白),β2-MG(β2微球蛋白),Cystatin C(CYSC,胱抑素C)在2型糖尿病患者中的表达水平及相关性研究.方法 将121例2型糖尿病患者分为糖尿病肾脏病低危组(低危组,n=67例)、中危组(中危组,n=39)、高(极高)危组(高危组,n=15例)和50例健康对照组.采用胶体金法测定血清和尿液中的NGAL、酶联免疫吸附法测定血尿CYSC、β2-微球蛋白水平,同时测定各组肾功能、血脂全套、甲状腺激素水平等.结果 与健康对照组相比,糖尿病患者的血清NGAL、CYSC、β2-MG、BUN(尿素氮)、CR(肌酐)、LDL-C(低密度胆固醇)、TG(甘油三酯)、FT4(游离甲状腺激素)水平显著升高(P＜0.05),随着糖尿病肾脏疾病危险分层的升高,血NGAL、CYSC、β2-MG、BUN、CR均呈上升趋势.血NGAL与尿ACR(尿微量白蛋白肌酐比值)、血BUN、CR、UA(尿酸)、CYSC、β2-MG、FT4、GFR(肾小球滤过率)相关,多元线性回归分析显示血BUN、CR、血β2-MG、FT4、TC、LDL-C是影响血NGAL水平的独立危险因素.结论 血NGAL水平升高与高血糖及糖尿病肾脏疾病的发生相关,血NGAL的检测对早期糖尿病肾脏疾病的病情评估有临床意义,血NGAL、CYSC、β2-MG及常规肾功能的联合检测可提高早期糖尿病肾脏疾病的检出率.

摘要： 目的 探讨miR-126、Transferrin、miR-133b、miR-342和Cystatin C对2型糖尿病肾病的诊断价值.方法 选取2型糖尿病肾病患者30例为糖尿病肾病组,2型糖尿病非肾病患者30例为糖尿病非肾病组,同时选取健康体检者30例为对照组,检测3组受试者血清中miR-126和Transferrin的水平,尿中miR-133b、miR-342和Cystatin C的水平.用ROC曲线下面积分析miR-126、Transferrin、miR-133b、miR-342和Cystatin C对2型糖尿病肾病的诊断价值.结果 糖尿病肾病患者的miR-126的相对表达量明显低于糖尿病非肾病患者和健康体检者(P<0.05),而其miR-133b和miR-342的相对表达量、Cystatin C和Transferrin的表达量明显高于糖尿病非肾病患者和健康体检者(P<0.05).糖尿病非肾病患者miR-126的相对表达量明显低于健康体检者(P<0.05),而其miR-133b的相对表达量和Cystatin C和Transferrin的表达量明显高于健康体检者(P<0.05).2型糖尿病肾病患者与非2型糖尿病肾病人员的miR-126、miR-133b、miR-342、Cystatin C和Transferrin的灵敏度分别为96％、83％、70％、77％、83％;特异性分别为41％、75％、82％、88％、80％.四项联合检测的灵敏度为97％、特异性为77％,准确率为83％.结论 miR-126、Transferrin、miR-133b、miR-342和CystatinC可作为诊断2型糖尿病肾病的潜在标志物.

摘要： 目的 探讨在食管癌(EC)发生、发展中,组织蛋白酶B(cathepsin B)与半胱氨酸蛋白酶抑制剂C(cystatin C)的表达及意义,并研究其在EC中的作用.方法 选取EC切除术患者120例、癌旁组织120例与食管高级别上皮内瘤变患者54例,取其病理标本及临床病理资料,采取免疫组化法检测cathepsin B、cystatin C表达,观测其阳性率及与5年生存率的关系.结果 EC组织、癌旁正常组织与食管高级别上皮内瘤变组织中,cystatin C阳性率分别为37.50%、86.67%、66.67%,cathepsin B阳性率分别为47.50%、0.00%、7.41%,差异均有统计学意义(P0.05);cathepsin B阳性组5年生存率显著低于阴性组,差异有统计学意义(P<0.05).结论 cathepsin B可作为EC诊断的有效指标,但cathepsin B与患者5年生存率显著相关,而cystatin C不能作为独立提示预后的因素.

摘要： 目的:探讨血清cystatin C水平与多普勒超声颈动脉斑块检查对脑梗死诊断的应用研究.方法:选取2015年1月至2016年12月在齐医附属二院神经内科诊治患者72例作为研究对象,分成脑梗死组和非脑梗死组.采用独立样本t检验比较两组患者血清cystatin C浓度、斑块厚度及面积,采用 χ2检验比较两组患者斑块性质,以P0.05).结论:高浓度血清cystatin C与彩色多普勒超声检查颈动脉非稳定性斑块可以诊断脑梗死.

摘要： The development of formulas estimating glomerular filtration rate(eG FR) from serum creatinine and cystatin C and accounting for certain variables affecting the production rate of these biomarkers, including ethnicity, gender and age, has led to the current scheme of diagnosing and staging chronic kidney disease(CKD),which is based on e GFR values and albuminuria.This scheme has been applied extensively in various populations and has led to the current estimates of prevalence of CKD. In addition, this scheme is applied in clinical studies evaluating the risks of CKD and the efficacy of various interventions directed towards improving its course. Disagreements between creatinine-based and cystatin-based e GFR values and between e GFR values and measured GFR have been reported in various cohorts. These disagreements are the consequence of variations in the rate of production and in factors, other than GFR, affecting the rate of removal of creatinine and cystatin C. The disagreements create limitations for all e GFR formulas developed so far. The main limitations are low sensitivity in detecting early CKD in several subjects, e.g., those with hyperfiltration, and poor prediction of the course of CKD. Research efforts in CKD are currently directed towards identification of biomarkers that are better indices of GFR than the current biomarkers and,particularly, biomarkers of early renal tissue injury.

摘要： AIM To investigate the association between carotid atherosclerosis and cystatin C(CysC) and to determine the optimal CysC cut-off value.METHODS One hundred twenty-eight subjects were included in this study. Atherosclerosis was defined as a maximum carotid plaque thickness(MCPT) of greater than 2 mm. A receiver operating characteristic curve analysis was used to determine the diagnostic value of serum CysC for atherosclerosis. The subjects were divided into two groups according to the CysC cut-off value. We screenedfor diabetes, hypertension, dyslipidemia, smoking status, alcohol consumption, and exercise behavior. The association between atherosclerosis and CysC levels was assessed using multivariate analysis.RESULTS The subjects were then divided into two groups according to the CysC cut-off value(0.73 mg/L). The median age of the high CysC group was 72 years(85% males), whereas that of the low CysC group was 61 years(63% males). The CysC levels were significantly correlated with Cr and estimated glomerular filtration rate(eGFR) values. Bodymass index, visceral fat area, hypertension, diabetes mellitus, and MCPT were significantly higher in the high CysC group than in the low CysC group. Furthermore, the eG FR was significantly lower in the high CysC group. Regarding lifestyle habits, only the exercise level was lower in the high CysC group than in the low CysC group. Multivariate analysis, adjusted for age and sex, revealed that high CysC levels were significantly associated with an MCPT of ≥ 2 mm(odds ratio: 2.92; 95%CI: 1.13-7.99).CONCLUSION Higher CysC levels were associated with an MCPT of ≥ 2 mm. The CysC cut-off value of 0.73 mg/L appears to aid in the diagnosis of atherosclerosis.

摘要： 主要针对人血清肌酐、Cystatin C以及尿总蛋白和白蛋白测定中的方法以及会遇到的问题进行阐述和总结，对临床实践具有指导意义。

摘要： 主要针对人血清肌酐、Cystatin C以及尿总蛋白和白蛋白测定中的方法以及会遇到的问题进行阐述和总结，对临床实践具有指导意义。

摘要： 主要针对人血清肌酐、Cystatin C以及尿总蛋白和白蛋白测定中的方法以及会遇到的问题进行阐述和总结，对临床实践具有指导意义。

摘要： 主要针对人血清肌酐、Cystatin C以及尿总蛋白和白蛋白测定中的方法以及会遇到的问题进行阐述和总结，对临床实践具有指导意义。

摘要： 主要针对人血清肌酐、Cystatin C以及尿总蛋白和白蛋白测定中的方法以及会遇到的问题进行阐述和总结，对临床实践具有指导意义。

摘要： Cat B属于蛋白酶类中的半胱氨酸蛋白酶,传统上认为半胱氨酸蛋白酶是降解蛋白的溶酶体酶。其生理作用就是通过溶酶体降解进入细胞内的胞外蛋白质、激素和被吞噬的细菌,进行细胞内消化,从而使蛋白质的合成与降解保持相对的平衡。在肿瘤组织中,肿瘤细胞和基质细胞分泌的Cat B能降解蛋白聚糖、LN、FN和Ⅳ型胶原等多种细胞外基质成份,破坏黏膜屏障,促进肿瘤细胞向深部组织浸润,从而为癌细胞的移动打开通道。Cys C作为一种半胱氨酸蛋白酶抑制物,具有保护细胞及组织免受各种不适当的内源或外源蛋白酶水解的作用,同时它也被认为是Cat B最主要的抑制物。本研究旨在检测两者在胃肠道肿瘤及其癌旁组织中的表达,初步探讨其与肿瘤发生发展过程中的关系。

摘要： Cat B属于蛋白酶类中的半胱氨酸蛋白酶,传统上认为半胱氨酸蛋白酶是降解蛋白的溶酶体酶。其生理作用就是通过溶酶体降解进入细胞内的胞外蛋白质、激素和被吞噬的细菌,进行细胞内消化,从而使蛋白质的合成与降解保持相对的平衡。在肿瘤组织中,肿瘤细胞和基质细胞分泌的Cat B能降解蛋白聚糖、LN、FN和Ⅳ型胶原等多种细胞外基质成份,破坏黏膜屏障,促进肿瘤细胞向深部组织浸润,从而为癌细胞的移动打开通道。Cys C作为一种半胱氨酸蛋白酶抑制物,具有保护细胞及组织免受各种不适当的内源或外源蛋白酶水解的作用,同时它也被认为是Cat B最主要的抑制物。本研究旨在检测两者在胃肠道肿瘤及其癌旁组织中的表达,初步探讨其与肿瘤发生发展过程中的关系。

摘要： Cat B属于蛋白酶类中的半胱氨酸蛋白酶,传统上认为半胱氨酸蛋白酶是降解蛋白的溶酶体酶。其生理作用就是通过溶酶体降解进入细胞内的胞外蛋白质、激素和被吞噬的细菌,进行细胞内消化,从而使蛋白质的合成与降解保持相对的平衡。在肿瘤组织中,肿瘤细胞和基质细胞分泌的Cat B能降解蛋白聚糖、LN、FN和Ⅳ型胶原等多种细胞外基质成份,破坏黏膜屏障,促进肿瘤细胞向深部组织浸润,从而为癌细胞的移动打开通道。Cys C作为一种半胱氨酸蛋白酶抑制物,具有保护细胞及组织免受各种不适当的内源或外源蛋白酶水解的作用,同时它也被认为是Cat B最主要的抑制物。本研究旨在检测两者在胃肠道肿瘤及其癌旁组织中的表达,初步探讨其与肿瘤发生发展过程中的关系。

摘要： Cat B属于蛋白酶类中的半胱氨酸蛋白酶,传统上认为半胱氨酸蛋白酶是降解蛋白的溶酶体酶。其生理作用就是通过溶酶体降解进入细胞内的胞外蛋白质、激素和被吞噬的细菌,进行细胞内消化,从而使蛋白质的合成与降解保持相对的平衡。在肿瘤组织中,肿瘤细胞和基质细胞分泌的Cat B能降解蛋白聚糖、LN、FN和Ⅳ型胶原等多种细胞外基质成份,破坏黏膜屏障,促进肿瘤细胞向深部组织浸润,从而为癌细胞的移动打开通道。Cys C作为一种半胱氨酸蛋白酶抑制物,具有保护细胞及组织免受各种不适当的内源或外源蛋白酶水解的作用,同时它也被认为是Cat B最主要的抑制物。本研究旨在检测两者在胃肠道肿瘤及其癌旁组织中的表达,初步探讨其与肿瘤发生发展过程中的关系。

摘要： Cat B属于蛋白酶类中的半胱氨酸蛋白酶,传统上认为半胱氨酸蛋白酶是降解蛋白的溶酶体酶。其生理作用就是通过溶酶体降解进入细胞内的胞外蛋白质、激素和被吞噬的细菌,进行细胞内消化,从而使蛋白质的合成与降解保持相对的平衡。在肿瘤组织中,肿瘤细胞和基质细胞分泌的Cat B能降解蛋白聚糖、LN、FN和Ⅳ型胶原等多种细胞外基质成份,破坏黏膜屏障,促进肿瘤细胞向深部组织浸润,从而为癌细胞的移动打开通道。Cys C作为一种半胱氨酸蛋白酶抑制物,具有保护细胞及组织免受各种不适当的内源或外源蛋白酶水解的作用,同时它也被认为是Cat B最主要的抑制物。本研究旨在检测两者在胃肠道肿瘤及其癌旁组织中的表达,初步探讨其与肿瘤发生发展过程中的关系。